Leo Pharma
Clinical trials sponsored by Leo Pharma, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame severe eczema in kids as young as 6 months Results expected Oct 2026 (estimated)
- New cream shows promise for painful hand and foot pustules Results expected Dec 2026 (estimated)
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Phase 4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Phase 2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New study tracks Real-World relief for stubborn hand eczema
Disease control By invitation onlyThis study follows 1000 adults with moderate to severe chronic hand eczema who are prescribed delgocitinib cream by their doctor. Researchers will track changes in skin symptoms and any side effects over 52 weeks to see how well the cream works in real-life settings. The goal is …
Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
LEO Pharma's new drug study pulled before any volunteers enrolled
Knowledge-focused CancelledThis was an early-stage study designed to check the safety and tolerability of a new drug called LEO 142397 in healthy people. The study was planned in two parts: one group would get a single dose, and another would take it daily for two weeks. However, the study was withdrawn be…
Phase 1 • Sponsor: LEO Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC